The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prognostic values of microRNAs in phase III clinical trial gastric cancer patients treated with S-1/oxaliplatin or doxifluridine/oxaliplatin.
J. Jiang
No relevant relationships to disclose
C. Wu
No relevant relationships to disclose
X. Zheng
No relevant relationships to disclose
Q. Zhou
No relevant relationships to disclose
X. Zhang
No relevant relationships to disclose
X. Xu
No relevant relationships to disclose
B. Lu
No relevant relationships to disclose
J. Ju
No relevant relationships to disclose